Chief Scientific Officer Or Yat Sun was granted 9,750 shares and covered exercise/tax liability with 4,324 shares, increasing direct ownership by 1% to 374,535 units (SEC Form 4)

$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ENTA alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Or Yat Sun

(Last) (First) (Middle)
C/O ENANTA PHARMACEUTICALS, INC.
4 KINGSBURY AVENUE

(Street)
WATERTOWN MA 02472

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2025 A 9,750(1) A $0 378,859 D
Common Stock 02/12/2025 F 4,324(2) D $5.59 374,535 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.
2. Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.
/s/ Matthew Kowalsky as attorney-in-fact 02/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ENTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENTA

DatePrice TargetRatingAnalyst
8/9/2023$14.00Neutral → Underweight
JP Morgan
8/8/2023$49.00 → $18.00Buy → Hold
Jefferies
12/9/2022$56.00Buy
H.C. Wainwright
7/6/2022$62.00In-line → Outperform
Evercore ISI
6/1/2022$39.00Underperform → In-line
Evercore ISI
2/9/2022$80.00 → $68.00Market Perform
SVB Leerink
1/13/2022$85.00 → $80.00Market Perform
SVB Leerink
11/24/2021$55.00 → $73.00Perform
Oppenheimer
More analyst ratings

$ENTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company's respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil. Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation. Data from a Phase 2 study of zelicapavir, an N-protei

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

    On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ENTA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENTA
SEC Filings

See more

$ENTA
Leadership Updates

Live Leadership Updates

See more
  • Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Financials

Live finance-specific insights

See more
  • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

    On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

    Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and webcast to discuss data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

    Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). Conference Call and Webcast Information The live webcast on Monday, December 9 at 8:30 a.m. ET can be accessed at "Events & Pres

    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more